Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | QPCT | Q16769 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.30 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.30 |
| ▸ | CHKA | P35790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1268157 | 0.98 | CYP2B6 (0.35) | NFKB1QPCTHSD17B10QPCTLCYP2B6 | |
| SCHEMBL21490423 | 0.98 | CYP2B6 (0.35) | NFKB1QPCTHSD17B10QPCTLCYP2B6 | |
| Hydrochloric Acid SCHEMBL8473908 | 0.93 | NFKB1 (0.33) | NFKB1QPCTHSD17B10QPCTLCYP2B6 | |
| Pyrimidine SCHEMBL28401409 | 0.88 | CYP1A2 (0.32) | CYP2B6CYP1A2CYP3A4CYP2D6MAPT | |
| SCHEMBL20445968 | 0.82 | CHRNB2 (0.36) | — | |
| SCHEMBL8060339 | 0.79 | NFKB1 (0.36) | NFKB1QPCTHSD17B10QPCTLCYP1A2 | |
| SCHEMBL8129527 | 0.79 | ADRB2 (0.36) | NFKB1QPCTHSD17B10QPCTL | |
| SCHEMBL21047582 | 0.76 | CYP11B1 (0.33) | QPCT | |
| SCHEMBL21047688 | 0.75 | ACHE (0.32) | — | |
| Fluoride SCHEMBL7489522 | 0.74 | CYP1A2 (0.33) | NFKB1QPCTHSD17B10QPCTLCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207531-B | Fused imidazole derivatives as TGF-beta inhibitors | 里格尔药品股份有限公司 | 2021-05-25 | — | — | CN | disclosed |
| CN-109772459-A | A kind of chirality polyacid Base Metal organic framework materials and its preparation method and application | 河南大学 | 2019-05-21 | — | — | CN | disclosed |
| EP-3355699-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR INHIBITING SUV39H2 | OncoTherapy Science, Inc. (JP) | 2018-08-08 | — | — | EP | disclosed |
| EP-3221318-A1 | FUSED IMIDAZOLE DERIVATIVES AS TGF-BETA INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| CN-104487429-B | Heterocycle chromocor derivative, composition and relative method | 爱默蕾大学 | 2017-07-14 | — | — | CN | disclosed |
| WO-2016081364-A1 | FUSED IMIDAZOLE DERIVATIVES AS TGF-BETA INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-26 | — | — | WO | disclosed |
| CN-102448956-B | Hepatitis c virus inhibitors | BRISTOL MYERS SQUIBB CO | 2015-05-06 | — | — | CN | disclosed |
| EP-2414350-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8796466-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-05 | — | — | US | disclosed |
| CN-102414199-B | Diaryl ethers | TIBOTEC PHARM LTD | 2014-03-05 | — | — | CN | disclosed |
| US-6362188-B1 | ANTICANCER AGENTS | SCHERING CORPORATION | 2002-03-26 | — | — | US | disclosed |
| US-20010039292-A1 | Lipoic acid analogs | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION | 2001-11-08 | — | — | US | disclosed |
| US-6235772-B1 | OXIDATION RESISTANCE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASES; BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-05-22 | — | — | US | disclosed |
| EP-1061914-A1 | LIPOIC ACID ANALOGS | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-12-27 | — | — | EP | disclosed |
| US-6090842-A | REDUCES CONCENTRATION OF OXYGEN IN CELLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-07-18 | — | — | US | disclosed |
| CN-1252806-A | Dolastatin-15 derivatives having carbonyl and heterocyclic functional groups at the C-terminus | BASF AG (DE) | 2000-05-10 | — | — | CN | disclosed |
| EP-0981539-A1 | DOLASTATIN 15 DERIVATIVES WITH CARBONYL AND HETEROCYCLIC FUNCTIONALITIES AT THE C-TERMINUS | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-01 | — | — | EP | disclosed |
| US-5965537-A | ANTICANCER AGENTS; WATER SOLUBILITY | BASF AKTIENGESELLSCHAFT (DE) | 1999-10-12 | — | — | US | disclosed |
| WO-1999045922-A1 | LIPOIC ACID ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1998040400-A1 | DOLASTATIN 15 DERIVATIVES WITH CARBONYL AND HETEROCYCLIC FUNCTIONALITIES AT THE C-TERMINUS | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039292-A1 | Lipoic acid analogs | ALOX5, ALOX15, ACSL5 | NFKB1 484/4885QPCT 1652/4885HSD17B10 96/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.